What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review.

Autor: Tochel C; Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK., Smith M; Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK., Baldwin H; Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; University of Oxford, Oxford, UK., Gustavsson A; Quantify Research, Stockholm, Sweden.; Department of Neurobiology, Care Sciences & Society, Karolinska Institute, Stockholm, Sweden.; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Ly A; Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK., Bexelius C; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Nelson M; Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK., Bintener C; Alzheimer Europe, Luxembourg City, Luxembourg., Fantoni E; GE Healthcare, Life Sciences, Amersham, UK., Garre-Olmo J; Girona Biomedical Research Institute (IdibGI), Girona, Catalonia, Spain., Janssen O; Department of Psychiatry & Neuropsychology, School for Mental Health & Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands., Jindra C; Department of Psychiatry, University of Oxford, Oxford, UK., Jørgensen IF; Novo Nordisk Foundation Center for Protein Research, Faculty of Health & Medical Sciences, University of Copenhagen, Copenhagen, Denmark., McKeown A; University of Oxford, Oxford, UK., Öztürk B; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark., Ponjoan A; Girona Biomedical Research Institute (IdibGI), Girona, Catalonia, Spain.; Vascular Health Research Group (ISV-Girona), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Catalonia, Spain., Potashman MH; Biogen, Cambridge, MA, USA., Reed C; Eli Lilly and Company Limited, Windlesham, UK., Roncancio-Diaz E; GE Healthcare, Life Sciences, Amersham, UK., Vos S; Department of Psychiatry & Neuropsychology, School for Mental Health & Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands., Sudlow C; Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia (Amsterdam, Netherlands) [Alzheimers Dement (Amst)] 2019 Mar 07; Vol. 11, pp. 231-247. Date of Electronic Publication: 2019 Mar 07 (Print Publication: 2019).
DOI: 10.1016/j.dadm.2018.12.003
Abstrakt: Introduction: Clinical trials involving patients with Alzheimer's disease (AD) continue to try to identify disease-modifying treatments. Although trials are designed to meet regulatory and registration requirements, many do not measure outcomes of the disease most relevant to key stakeholders.
Methods: A systematic review sought research that elicited information from people with AD, their caregivers, and health-care professionals on which outcomes of the disease were important. Studies published in any language between 2008 and 2017 were included.
Results: Participants in 34 studies described 32 outcomes of AD. These included clinical (memory, mental health), practical (ability to undertake activities of daily living, access to health information), and personal (desire for patient autonomy, maintenance of identity) outcomes of the disease.
Discussion: Evidence elicited directly from the people most affected by AD reveals a range of disease outcomes that are relevant to them but are not commonly captured in clinical trials of new treatments.
Databáze: MEDLINE
Externí odkaz: